The Asia Pacific myopia treatment market was valued at US$ 3.09 billion in 2022 and is expected to reach US$ 6.34 billion by 2030; it is estimated to register a CAGR of 9.4% from 2022 to 2030.
The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia.
The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients.
Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
In Asia Pacific, China held the largest market share for Asia Pacific myopia treatment market in 2022. The market growth is primarily attributed to the aging population, the increasing prevalence of myopia, and the rising emphasis on preventive care. For instance, according to a study published by the Population Reference Bureau in 2020, the old-age population of China is expected to reach ~366 million by 2050. Moreover, according to the same estimates, around 26% of China's population will be over 65 by 2050, up from 12% in 2020. Such an extensively increasing geriatric population is anticipated to offer lucrative opportunities for the increased demand for products in the country.
The country is also witnessing considerable growth in the prevalence of myopia, particularly in children, which is likely to increase the adoption of treatments in China. For instance, preschoolers and primary and secondary school students in China had a 50.2% prevalence of myopia in 2019, according to the British Journal of Ophthalmology. Additionally, according to the same source, 54.71% of children and adolescents between the ages of 6 and 16 had myopia overall in 2021. Thus, the increasing geriatric population and the increasing prevalence of myopia are driving the market growth.
Rising Availability of Advanced Technologies for Treating the Targeted Myopia Boosts Asia Pacific Myopia Treatment Market
The rising availability of advanced technologies for treating targeted myopia is a significant opportunity for the myopia treatment market. Advances in technologies such as laser-assisted in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lenses (ICL) have made it possible to correct myopia more effectively and with fewer complications. Various ground-breaking data were also presented during the congress; over 30 abstracts backed by Johnson & Johnson Vision have been approved for presentation. Surgeons can apply the innovative SILK (i.e., Smooth Incision Lenticule Keratomileusis) treatment to treat myopic patients who have astigmatism or do not utilize the ELITATM Platform.The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia.
The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients.
Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
Asia Pacific Myopia Treatment Market Overview
Asia Pacific myopia treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. This region accounted for over 30.14% of the Asia Pacific myopia treatment market in 2022 owing to the increasing aging population, rising number of research studies, growing government support, and increasing eye-related disorders in the region.In Asia Pacific, China held the largest market share for Asia Pacific myopia treatment market in 2022. The market growth is primarily attributed to the aging population, the increasing prevalence of myopia, and the rising emphasis on preventive care. For instance, according to a study published by the Population Reference Bureau in 2020, the old-age population of China is expected to reach ~366 million by 2050. Moreover, according to the same estimates, around 26% of China's population will be over 65 by 2050, up from 12% in 2020. Such an extensively increasing geriatric population is anticipated to offer lucrative opportunities for the increased demand for products in the country.
The country is also witnessing considerable growth in the prevalence of myopia, particularly in children, which is likely to increase the adoption of treatments in China. For instance, preschoolers and primary and secondary school students in China had a 50.2% prevalence of myopia in 2019, according to the British Journal of Ophthalmology. Additionally, according to the same source, 54.71% of children and adolescents between the ages of 6 and 16 had myopia overall in 2021. Thus, the increasing geriatric population and the increasing prevalence of myopia are driving the market growth.
Asia Pacific Myopia Treatment Market Segmentation
The Asia Pacific myopia treatment market is categorized into type, treatment, age group, end user, and country.- Based on type, the Asia Pacific myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Asia Pacific myopia treatment market share in 2022.
- In terms of treatment, the Asia Pacific myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Asia Pacific myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
- By age group, the Asia Pacific myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Asia Pacific myopia treatment market share in 2022.
- Based on end user, the Asia Pacific myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Asia Pacific myopia treatment market share in 2022.
- Based on country, the Asia Pacific myopia treatment market is categorized into Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific myopia treatment market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Myopia Treatment Market Landscape
5. Asia Pacific Myopia Treatment Market - Key Market Dynamics
7. Asia Pacific Myopia Treatment Market Analysis - by Type
8. Asia Pacific Myopia Treatment Market Analysis - by Treatment
9. Asia Pacific Myopia Treatment Market Analysis - by Age Group
10. Asia Pacific Myopia Treatment Market Analysis - by End User
11. Asia Pacific Myopia Treatment Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Bausch Health Companies Inc
- Alcon AG
- CooperVision Inc
- Johnson & Johnson Vision Care Inc
- Nidek Co Ltd
- Haag-Streit AG
- Carl Zeiss AG
